Laboratory for Experimental Immunology and Immunotherapy, Nikolaus-Fiebiger-Centre for Molecular Medicine, Medical Department III, University of Erlangen-Nuremberg, Glückstr. 6, 91054, Erlangen, Germany.
Ann Hematol. 2010 Jul;89 Suppl 1:25-30. doi: 10.1007/s00277-010-0915-3. Epub 2010 Feb 24.
Immune thrombocytopenia (ITP) can become a life-threatening condition that requires immediate medical attention. The loss in platelet numbers during ITP can be induced by a variety of triggers. Anti-platelet antibodies of several isotypes and subclasses are a major cause for ITP and are a hallmark of many complex autoimmune diseases such as systemic lupus erythematosus. Mouse models have been important to understand the effector pathways involved in antibody-mediated platelet depletion. Therapeutic interventions based on these results have been proven successful in treating human ITP, thus validating the use of these model systems. One major problem that remains to be answered is which cell populations are crucial for platelet removal. Targeting these cells directly might be a novel therapeutic strategy and will also be important to understand the underlying biological mechanisms.
免疫性血小板减少症 (ITP) 可能会成为危及生命的疾病,需要立即就医。ITP 期间血小板数量的减少可能由多种诱因引起。几种同种型和亚类的抗血小板抗体是 ITP 的主要原因,也是许多复杂自身免疫性疾病(如系统性红斑狼疮)的标志。小鼠模型对于了解抗体介导的血小板消耗所涉及的效应途径非常重要。基于这些结果的治疗干预措施已被证明对治疗人类 ITP 有效,从而验证了这些模型系统的使用。仍有待回答的一个主要问题是哪些细胞群体对于血小板清除至关重要。直接针对这些细胞可能是一种新的治疗策略,对于了解潜在的生物学机制也很重要。